| Biological Information | |
|---|---|
| Background Information: | B-RAF plays a role in regulating the MAP kinase/ERK signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene, most commonly the V600E mutation, are the most frequently identified cancer-causing mutations in melanoma, and have been identified in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of lung. Mutations in this gene are also associated with cardiofaciocutaneous, Noonan, and Costello syndromes, which exhibit overlapping phenotypes.
GenBank NM_004333. The V599E mutation is thought to mimic phosphorylation of the native enzyme, resulting in a protein with high activity and leading to constitutive ERK activation. As B-Raf is commonly activated by somatic point mutation in human cancer, it may provide a new therapeutic approach to malignant melanoma. (Davies H., et al., Nature, 2002. 417: 949-54, and Mercer KE., & Pritchard CA., Biochim Biophys Acta. 2003. 1653: 25-40) |
| Target Class: | Kinase |
| Family: | Ser/Thr Kinase |
| Accession Number: | NM_004333.3 |
| Target Name: | B-Raf |
| Target Aliases: | BRAF, BRAF1, B-Raf, MGC126806, RAFB1, p94, MGC138284, B-raf-1, BRAF V600E, B-RAF V600E |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 6 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
B-Raf (V599E), active
N-terminal GST-tagged recombinant, human B-Raf amino acids 416-end, containing a V599E mutation (also designated V600E).
Datasheets
14-557x Datasheet
View Document